Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Go back to Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 0.53 -0.04 (7.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.57 | 52 Week High | $9.58 | |||
| Open | $0.58 | 52 Week Low | $2.34 | |||
| Day High | $0.63 | P/E | N/A | |||
| Day Low | $0.51 | EPS | $-0.34 | |||
| Volume | 1,791,081 | |||||
